Recent advances in the understanding and treatment of cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 4, Issue 3, 1998, Pages 130-134

  Resnikoff, Joseph R ^a   Conrad, Douglas J ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CHILD; CYSTIC FIBROSIS; DRUG COMBINATION; GENE THERAPY; HUMAN; LUNG TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; PROGNOSIS; REVIEW;

ADULT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; GENE THERAPY; HUMANS; LUNG TRANSPLANTATION; PROGNOSIS;

EID: 0032060761     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Smith JJ, Travis SM, Greenberg EP, Welsh MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996, 85:229-236. This in vitro study describes a reversible, salt-sensitive defect in an antibacterial activity from secretions of CF airway epithelial cells. This paper implicates nonspecific host defenses in the pulmonary pathophysiology of CF.
2. Knowles M, Robinson J, Wood R, Pue C: Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest 1997, 100:2588-2595.
3. Widdicombe J, Fischer H, Lee CY-C, Uyekubo S, Miller S: Elemental composition of airway surface liquid. Pediatr Pulmonol 1997, 14(suppl S1.1):74-75.
4. Joris L, Dab I, Quinton PM: Elemental composition of human airway surface fluid in healthy and diseased airways. Am Rev Respir Dis 1993, 148(6 Pt 1):1633-1637.
5. Miyakawa Y, Ratnakar P, Rao AG, et al.: In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Infect Immun 1996, 64:926-932.
6. Porter EM, van Dam E, Valore EV, Ganz T: Broad-spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun 1997, 65:2396-2401.
7. Lencer WI, Cheung G, Strohmeier GR, et al.: Induction of epithelial chloride secretion by channel-forming cryptdins 2 and 3. Proc Natl Acad Sci U S A 1997, 94:8585-8589.
8. Van Wetering S, Mannesse-Lazeroms SP, Dijkman JH, Hiemstra PS: Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J Leukoc Biol 1997, 62:217-226.
9. Van Wetering S, Mannesse-Lazeroms SP, Van Sterkenburg MA, Daha MR, Dijkman JH, Hiemstra PS: Effect of defensins on interleukin-8 synthesis in airway epithelial cells. Am J Physiol 1997, 272(5 Pt 1):L888-L896.
10. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM: Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997, 88:553-560. The authors studied a human bronchial xenograft model in mice and demonstrated that CF airway secretions exhibit a defect in bacterial killing. Antisense oligonucleotides which inhibit expression of human β-defensin-1 block bacterial killing in secretions from non-CF grafts. Expression of CFTR in CF grafts corrected the bacterial killing defect.
11. Olivier KN, Yankaskas JR, Knowles MR: Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Semin Respir Infect 1996, 11:272-284.
12. Tomashefski JF Jr, Stern RC, Demko CA, Doershuk CF: Nontuberculous mycobacteria in cystic fibrosis: an autopsy study. Am J Respir Crit Care Med 1996, 154 (2 Pt 1):523-528.
13. Fuchs HJ, Borowitz DS, Christiansen DH, et al.: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function In patients with cystic fibrosis: the Pulmozyme Study Group. N Engl J Med 1994, 331:637-642.
14. Ramsey B, Burns J, Smith A: Safety and efficacy of tobramycin solution for inhalation in patients with cystic fibrosis: the results of two phase III placebo controlled clinical trials. Pediatr Pulmonol 1997, 14(suppl S10.3):137-138. Summarizes the results of two multicenter trials looking at the effects of alternate-month maintenance therapy of inhaled tobramycin. After 5 months, the treatment group had better spirometry and fewer pulmonary exacerbations. The data will be published in full form in the near future.
15. Catchpole CR, Andrews JM, Brenwald N, Wise R: A reassessment of the In-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997, 39:255-260.
16. Frederiksen B, Koch C, Hoiby N: Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997, 23:330-335.
17. Bauldoff GS, Nunley DR, Manzetti JD, Dauber JH, Keenan RJ: Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 1997, 64:748-752.
18. Church DA, Kanga JF, Kuhn RJ, et al.: Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997, 16:97-105; discussion 123-126.
19. Shah PL, Scott SF, Knight RA, Hodson ME: The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Eur Respir J 1996, 9:531-534.
20. Costello CM, O'Connor CM, Finlay GA, Shiels P, FitzGerald MX, Hayes JP: Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis. Thorax 1996, 51:619-623.
21. McCoy K, Hamilton S, Johnson C: Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease: Pulmozyme Study Group. Chest 1996, 110:889-895. The first large, controlled study of DNase in very ill patients with CF. Spirometry improved in these patients following 12 weeks of maintenance therapy compared with a placebo group. The therapy was found to be safe but did not alter days of hospitalization or intravenous antibiotic usage.
22. Wilmott RW, Amin RS, Colin AA, et al.: Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996, 153(6 Pt 1):1914-1917.
23. Griffith BP, Hardesty RL, Armitage JM, et al.: A decade of lung transplantation. Ann Surg 1993, 218:310-318; discussion 318-320.
24. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR: The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997, 155:1699-1704.
25. Kaplan JM, Armentano D, Sparer TE, et al.: Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum Gene Ther 1997, 8:45-56.
26. Yang Y, Su Q, Wilson JM: Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996, 70:7209-7212.
27. van Ginkel FW, McGhee JR, Liu C, et al.: Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J Immunol 1997, 159:685-693.
28. Sparer TE, Wynn SG, Clark DJ, et al.: Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype. J Virol 1997, 71:2277-2784.
29. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM: Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996, 217:11-22.
30. Kay M: Development of recombinant adenoviral vectors for gene therapy. Pediatr Pulmonol 1996, 13(suppl S2.5):95-96.
31. Scaria A, St George JA, Gregory RJ, et al.: Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther 1997, 4:611-617.
32. McDonald RJ, Lukason MJ, Raabe OG, et al.: Safety of airway gene transfer with Ad2/CFTR2: aerosol administration in the nonhuman primate. Hum Gene Ther 1997, 8:411-422.
33. Dong JY, Wang D, Van Ginkel FW, Pascual DW, Frizzell RA: Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 1996, 7:319-331.
34. Bellon G, Michel-Calemard L, Thouvenot D, et al.: Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997, 8:15-25.
35. Chadwick SL, Kingston HD, Stern M, et al.: Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers. Gene Ther 1997, 4:937-942.
36. Porteous DJ, Dorin JR, McLachlan G, et al.: Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997, 4:210-218.
37. Rubenstein RC, McVeigh U, Flotte TR, Guggino WB, Zeitlin PL: CFTR gene transduction in neonatal rabbits using an adeno-associated virus (AAV) vector. Gene Ther 1997, 4:384-92.
38. Conrad CK, Allen SS, Afione SA, et al.: Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996, 3:658-668.
39. Rubenstein R, Egan M, Zeitlin P: In vitro pharmacologic resotration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997, 100:2457-2465.
40. Rubenstein R, Zeitlin P: A randomized, double blind, placebo-controlled trial of sodium 4-phenylbutyrate in delta F508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Pediatr Pulmonol 1997, 14(suppl A234):272.
41. Kelley TJ, Thomas K, Milgram LJ, Drumm ML: In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant delta F508 in murine nasal epithelium. Proc Natl Acad Sci U S A 1997, 94:2604-2608.
42. Kelly T, Milgram L, Hazel M, Capecchi M, Drumm M: Phosphodiesterase inhibitors as pharmacologic modulators of CFTR activity. Pediatr Pulmonol 1997, 14(suppl S8.2):126.
43. Arispe N, Pollard H, Ma J: Activation and Inhibition of CFTR chloride channels expressed in HEK293 cells by addition of CPX, DAX and DPC. Pediatr Pulmonol 1997, 14(suppl A231):271.
44. Haws CM, Nepomuceno IB, Krouse ME, et al.: Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am J Physiol 1996, 270(5 Pt 1):C1544-C1555.
45. Hwang TC, Wang F, Yang IC, Reenstra WW: Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 1997, 273(3 Pt 1):C988-C998.
46. Illek B, Yankaskas JR, Machen TE: cAMP and genistein stimulate HCO3-conductance through CFTR in human airway epithelia. Am J Physiol 1997, 272(4 Pt 1):L752-L761.
47. Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Boucher RC, Knowles MR: Effect of uridine 5′-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 1996, 153(6 Pt 1):1796-1801.